Phase I study of ACOU 085 in patients with age-related hearing loss
Latest Information Update: 19 Dec 2022
At a glance
- Drugs ACOU 085 (Primary)
- Indications Sensorineural hearing loss
- Focus Adverse reactions; First in man
- Sponsors Acousia Therapeutics
- 12 Dec 2022 Status changed from recruiting to completed, according to an Acousia Therapeutics media release.
- 12 Dec 2022 According to an Acousia Therapeutics media release, the final visit of the last patient treated in this study has been completed. The company has successful completed this study.
- 24 Nov 2022 According to an Acousia Therapeutics media release, the company expects to finish this first-in-man clinical Phase 1b study by late 2022